Cargando…
Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
BACKGROUND: Since giant cell tumors of bone (GCTB) and other giant cell rich tumors of bone (GCRTB) share the histological presence of osteoclastic giant cells and expression of RANK/RANKL, we hypothesized that GCRTB will respond similarly to denosumab as GCTB. The primary objective of this study wa...
Autores principales: | Lipplaa, Astrid, Schreuder, Willem H, Pichardo, Sarina E C, Gelderblom, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628576/ https://www.ncbi.nlm.nih.gov/pubmed/37449658 http://dx.doi.org/10.1093/oncolo/oyad196 |
Ejemplares similares
-
Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019) -
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone
por: Lipplaa, Astrid, et al.
Publicado: (2019) -
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
por: Li, Jian, et al.
Publicado: (2022) -
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
por: Tanimura, Keiko, et al.
Publicado: (2023) -
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
por: El Dika, Imane, et al.
Publicado: (2018)